GSK (GSK) announced that it has entered into an agreement with Chongqing Zhifei Biological Products to revise the terms on which Zhifei will commercialise GSK’s shingles vaccine, Shingrix, in mainland China. The revised agreement extends the original 3-year period during which Zhifei has exclusive rights to import, distribute and co-promote the vaccine in mainland China for an additional 8 years through to 2034, with revised expected volumes. Under the revised agreement, Zhifei also agrees to engage exclusively with GSK to explore a potential collaboration, with an initial term of 10 years, on the commercialisation of a respiratory syncytial virus vaccine in mainland China, subject to regulatory approval of the vaccine. This agreement amends the agreement previously announced in October 2023. Subject to the terms of the revised agreement, the parties expect Zhifei will purchase volumes of Shingrix, phased over time, with a potential total value to GSK of GBP 2.3bn over the 6-year period 2024-2029. Previously contracted minimum purchase levels no longer apply.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GSK:
- GSK price target lowered to 1,600 GBp from 1,820 GBp at Berenberg
- GSK announces EC approved single-vial presentation of Menveo
- GSK announces FDA accepeted for review a BLA for Blenrep
- Trump Trade: Trump Media considers developing crypto payment service
- Trump expected to pick Martin Makary to head FDA, Reuters reports
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
